Ocular Therapeutix (NASDAQ:OCUL)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a note issued to investors on Friday, March 9th. They currently have a $10.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 55.28% from the stock’s current price.
Other equities analysts have also recently issued reports about the company. Zacks Investment Research upgraded Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Saturday, November 11th. ValuEngine upgraded Ocular Therapeutix from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 3rd. BTIG Research upgraded Ocular Therapeutix from a “neutral” rating to a “buy” rating in a report on Friday, January 19th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $22.00 target price on shares of Ocular Therapeutix in a report on Thursday, March 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. Ocular Therapeutix currently has a consensus rating of “Buy” and an average price target of $11.70.
Shares of NASDAQ:OCUL traded down $0.07 during midday trading on Friday, reaching $6.44. 288,988 shares of the company traded hands, compared to its average volume of 508,653. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.22 and a current ratio of 3.23. Ocular Therapeutix has a 12 month low of $3.30 and a 12 month high of $11.79. The firm has a market cap of $242.68, a price-to-earnings ratio of -2.93 and a beta of 1.23.
Ocular Therapeutix (NASDAQ:OCUL) last posted its earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.44) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.58) by $0.14. Ocular Therapeutix had a negative return on equity of 145.73% and a negative net margin of 3,296.20%. The business had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $0.51 million. During the same period in the previous year, the business earned ($0.52) earnings per share. The firm’s revenue was up .0% on a year-over-year basis. equities analysts predict that Ocular Therapeutix will post -1.91 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jennison Associates LLC raised its position in Ocular Therapeutix by 1.0% during the 4th quarter. Jennison Associates LLC now owns 1,994,768 shares of the biopharmaceutical company’s stock valued at $8,877,000 after purchasing an additional 20,132 shares during the last quarter. BlackRock Inc. raised its position in Ocular Therapeutix by 0.8% during the 4th quarter. BlackRock Inc. now owns 1,418,577 shares of the biopharmaceutical company’s stock valued at $6,312,000 after purchasing an additional 11,293 shares during the last quarter. Columbus Circle Investors raised its position in Ocular Therapeutix by 85.7% during the 3rd quarter. Columbus Circle Investors now owns 1,072,395 shares of the biopharmaceutical company’s stock valued at $6,627,000 after purchasing an additional 494,867 shares during the last quarter. Vanguard Group Inc. raised its position in Ocular Therapeutix by 0.4% during the 2nd quarter. Vanguard Group Inc. now owns 905,456 shares of the biopharmaceutical company’s stock valued at $8,394,000 after purchasing an additional 3,194 shares during the last quarter. Finally, State Street Corp raised its position in Ocular Therapeutix by 12.3% during the 2nd quarter. State Street Corp now owns 371,923 shares of the biopharmaceutical company’s stock valued at $3,450,000 after purchasing an additional 40,782 shares during the last quarter. 36.24% of the stock is owned by institutional investors and hedge funds.
About Ocular Therapeutix
Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.